Table 1 Baseline characteristics
From: The impact of androgen deprivation therapy on the lipid profile in patients with prostate carcinoma
Orchidectomy | LHRH agonist | p value | |
|---|---|---|---|
Number | 29 | 40 | |
Age (years)* | 70.4 ± 5.7 | 69.1 ± 5.9 | 0.39 |
BMI (kg/m2)* | 22.8 ± 3.4 | 22.8 ± 3 | 0.71 |
Diabetes | 15 | 20 | 1 |
Hypertension | 14 | 17 | 0.82 |
Serum PSA (ng/ml)* | 55.4 ± 50.2 | 50.1 ± 45.3 | 0.64 |
Locally advanced/Metastatic prostate cancer (as per EAU definitions) | 14/15 | 18/22 | 0.81 |
Gleason score* | 8.1 ± 1.1 | 8.2 ± 1.2 | 0.48 |
CAB | 23 | 34 | 0.85 |